Icra sees pharma industry growth tapering to 7-10% over FY18-FY20Post published:July 4, 2017Post category:Industry NewsThe Indian pharma industry is likely to witness a slowdown in growth because of pricing pressure and regulatory interventions in the US, according to an Icra report Source: Livemint.com (http://www.livemint.com/rss/industry)Read more articles Previous PostIndoStar Capital close to acquiring ICICI Home Finance Next PostGST rates: Footwear to cost more as firms look to increase prices by 5-7% You Might Also Like Boston Dynamics Acquires Kinema Systems, Plans to Sell Pick Vision Technology Solution April 3, 2019 ABB uses swimming robots to help Australian silicon company enhance transformer inspections December 9, 2019 The impact of demonetisation and the preparations for GST June 28, 2017
ABB uses swimming robots to help Australian silicon company enhance transformer inspections December 9, 2019